Noven's Stavzor receives tentative FDA approval

12/26/2007 | Boston Globe (tiered subscription model), The · CNNMoney

Noven Pharmaceuticals announced the FDA granted tentative approval for Stavzor as treatment for manic episodes connected to bipolar disorder, epilepsy and migraine headaches. The Miami-based firm also said it expects final FDA approval to market Stavzor in the U.S. by the end of July 2008, after a similar drug from Abbott Laboratories, Depakote, loses exclusivity rights.

View Full Article in:

Boston Globe (tiered subscription model), The · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX